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Abstract
Since 1998, several serotypes of Bluetongue virus (BTV) have invaded several southern European countries. In 2006,
the unknown BTV serotype 8 (BTV8/net06) unexpectedly invaded North-West Europe and has resulted in the
largest BT-outbreak ever recorded. More recently, in 2008 BTV serotype 6 was reported in the Netherlands and
Germany. This virus, BTV6/net08, is closely related to modified-live vaccine virus serotype 6, except for genome
segment S10. This genome segment is closer related to that of vaccine virus serotype 2, and therefore BTV6/net08
is considered as a result of reassortment. Research on orbiviruses has been hampered by the lack of a genetic
modification method. Recently, reverse genetics has been developed for BTV based on ten in vitro synthesized
genomic RNAs. Here, we describe a targeted single-gene modification system for BTV based on the uptake of a
single in vitro synthesized viral positive-stranded RNA. cDNAs corresponding to BTV8/net06 genome segments S7
and S10 were obtained by gene synthesis and cloned downstream of the T7 RNA-polymerase promoter and
upstream of a unique site for a restriction enzyme at the 3’-terminus for run-off transcription. Monolayers of BSR
cells were infected by BTV6/net08, and subsequently transfected with purified in vitro synthesized, capped positive-
stranded S7 or S10 RNA from BTV8/net06 origin. “Synthetic” reassortants were rescued by endpoint dilutions, and
identified by serotype-specific PCR-assays for segment 2, and serogroup-specific PCRs followed by restriction
enzyme analysis or sequencing for S7 and S10 segments. The targeted single-gene modification system can also
be used to study functions of viral proteins by uptake of mutated genome segments. This method is also useful to
generate mutant orbiviruses for other serogroups of the genus Orbivirus for which reverse genetics has not been
developed yet.
Findings
Bluetongue (BT) is an arthropod-borne disease; trans-
mission to ruminants, including cattle, sheep, and goats,
occurs by bites of species of Culicoides. Bluetongue is
listed as a ‘notifiable disease’ by the Office International
des Epizooties (OIE) [1] causing severe hemorrhagic dis-
ease with fever, lameness, coronitis, swelling of the head
(particularly the lips and tongue) and death. Bluetongue
virus (BTV) belongs to the family Reoviridae, genus
Orbivirus [2].
The genome of BTV consists of ten linear double-
stranded RNA genome segments encoding the seven
structural proteins VP1 to VP7, and three nonstructural
proteins, NS1, NS2 and NS3/NS3a [3-7]. The two inner
layers of the BTV particle, identified as the ‘sub-core’
and ‘core’, are composed of major structural proteins
VP3 and VP7, and are encoded by genome segment S3
and S7. The innermost shell, the ‘subcore’ consists of
VP3 and surrounds one copy of each of the ten genome
segments and the three enzymatic structural proteins
VP1, VP4 and VP6, which are encoded by S1, S4 and
S9, respectively.
Since 1998, BTV serotypes 1, 2, 4, 9, and 16 have
invaded European countries around the Mediterranean
Basin. The outbreak by BTV8/net06 (sample nr. BTV-8
NET2006/04 in the dsRNA virus reference collection
(dsRNA-VRC) at IAH Pirbright, [8]) starting in August
2006 [9] has resulted in the largest BT-outbreak ever
recorded. More recently, BTV6/net08 (sample BTV-6
NET2008/05 in the dsRNA-VRC at IAH Pirbright, [10])
was reported in The Netherlands [11] and Germany
[12] in 2008. BTV6/net08 is closely related to modified-
live vaccine virus serotype 6, but genome segment S10
showed the highest homology (98.4%) with that of vac-
cine virus serotype 2 (RSAvvv2/02 in dsRNA-VRC).
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This suggested a reassortment between vaccine viruses
serotype 6 and serotype 2 resulting in BTV6/net08.
Maan et al. also suggested that BTV6/net08 was in the
process of reassorting with BTV8/net06, since the blood
of a PCR-positive cow contained two different S7
sequences, one of which (from the BTV6 vaccine) was
selected during virus isolation in cell-culture [10]. The
other S7 sequence (from the Northern field strain
BTV8/06) was predominantly found in blood of this
cow.
Research on BTV, including research on reassortment,
has already a long scientific record (reviewed by Roy
2005; [13]). Recently, a reverse genetics system for BTV
has been developed [14], and has been demonstrated to
be useful to generate mutants of BTV by genetic manip-
ulation of one or more of genome segments [15]. This
system needs, however, a set of ten complete cDNAs of
genome segments to rescue bluetongue virus from T7
derived RNA transcripts. Here, we describe a targeted
single-gene genetic modification system as an alternative
method for genetic modification of orbiviruses. This sys-
tem is based on the uptake of one in vitro synthesized
viral RNA in an ongoing infection. We have focused on
the uptake of genome segments S7 or S10 originating
from BTV8/net06 in BTV6/net08, although the method
is proposed to be broadly applicable for all genome seg-
ments and all orbiviruses.
Genome segments S7 and S10 were synthesized by
Genscript Corporation (Piscataway, NJ) based on the
identical sequences AM498057.2 and FJ183380.1 for S7,
and the identical sequences AM498060.1 and
FJ183383.1 for S10 of Genbank. cDNAs were cloned in
plasmid pUC57 under control of the T7 RNA-polymer-
ase promoter and a site for a restriction enzyme at the
3’-terminus for defined run-off transcription (Figure 1,
depicted from Boyce et al., [14]). Plasmids were main-
tained in E. coli DH5a, and were purified using QIAfil-
ter Plasmid Midi Kit (Qiagen).
Plasmid DNA was digested with BbsI for S7 or with
BsMBI for S10, and was purified by standard proce-
dures. One μg of digested plasmid DNA was used for
in vitro RNA run-off transcription with 5’ cap analogue
using the MESSAGE mMACHINE T7 Ultra Kit
(Ambion). In this reaction, a ratio of 4:1 of anti-reverse
cap analogue to rGTP was used. Synthesized RNA was
cleaned by use of MEGAclear columns (Ambion)
according to the manufacturer’s instructions, and eluted
RNA was stored at -80°C.
Monolayers of 105 BSR cells ([16], gift of P. Roy) were
infected at a multiplicity of infection (moi) of 0.1 with
BTV6/net08, which has been isolated on embryonated
eggs (e1), followed by three passages on BHK21 cells
(bhk3), and two passages on BSR cells (bsr2) (BTV6/
net08/e1/bhk3/bsr2). At one hr post infection (hpi),
infected monolayers were transfected with 400 ng
synthesized RNA transcripts of S7 or S10 using 1 μl
lipofectamine™2000 (1:2.5; 1 mg/ml Invitrogen) in Opti-
MEM® I Reduced Serum Medium according to manufac-
turer’s conditions for 4 hrs, after which it was refreshed
with 1 ml of Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 5% FBS and 1% of Penicil-
lin/Streptomycin/Fungizone. At 40 hpi, supernatants
were harvested, and virus was cloned by endpoint dilu-
tion in M96-wells on BSR cells. At 3 days post infection
(dpi), supernatants were collected from wells with cells
developing cytopathogenic effect (CPE).
Infection of the respective monolayers was confirmed
by immunostaining with monoclonal antibody (Mab)
produced by ATCC-CRL-1875 directed against VP7
(data not shown). Typically, viruses in 48 supernatants
were multiplied in M24 wells in BSR cells by adding 75
μl supernatant in 1 ml of DMEM supplemented with 5%
FBS and 1% of Penicillin/Streptomycin/Fungizone. After
development of CPE, 2-3 dpi, supernatants were col-
lected and stored at -80°C. Viral RNA was isolated from
200 μl of supernatant with the High Pure Viral RNA kit
(Roche).
A serogroup-specific duplex RT-PCR was used for
amplification of genome segment S7 [17]. For partial
amplification of genome segment S10, the in-house
developed serogroup-specific diagnostic RT-PCR-assay
was used [18]. Differentiation between both segments S7
and segments S10 was performed by either restriction
analysis or sequencing of amplicons. For S7, 5 μl of the
Figure 1 Schematic overview of plasmids containing the full-length BTV genome segment. A full-length BTV genome segment flanked by
a T7 promoter and a BsmBI (for S10) or BbsI (for S7) restriction enzyme site which defines the BTV 3’end sequence during transcription. The
nucleotides of the ultimate 5’- and 3’-ends of the BTV genome segment are presented in bold symbols. The sequence of the T7 promoter is
italicized, and the BsmBI site is underlined. The positions of the start of transcription and digestion by restriction enzymes for run-off
transcription are indicated by arrows.
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RT-PCR reaction was digested with PstI and BglII and
analyzed by agarose gel electrophoresis. For S10, gel-
purified amplicons were sequenced using the BigDye®
Terminator v3.1 Cycle Sequencing Kit (Applied Biosys-
tems, Foster City, IA, USA) in a ABI PRISM® 3130
Genetic Analyzer (Applied Biosystems, Foster City, IA,
USA). In order to genetically serotype the cloned
viruses, in-house developed serotype-specific PCR-assays
for serotypes 6 and 8, based on segment S2 of BTV,
were carried out using LightCycler RNA Master Hybri-
dization Probes kit and a LightCycler 2.0 PCR machine
(both supplied by Roche Diagnostics, Almere, Nether-
lands). For the BTV6-S2 serotype-specific RT-PCR for-
ward primer 5’-AGGAACAGTCGGCTTATCAC-3’,
reverse primer 5’-TTCGCTAATGTGCTTCTCCAT-3’
(Eurogentec b.v., Maastricht, Netherlands) and taqmanp-
robe 5’-6FAM- TTGTCAGCTTTACGCAAACCCCG-
BHQ-3’ (Tib MolBiol, Berlin, Germany) were used. For
the BTV8-S2 serotype-specific RT-PCR forward primer
5’-CGGAGACAGCGCAGTATGTA-3’, reverse primer
5’-CCTCGGTAGTATCCCTCACG-3’ (Eurogentec b.v.,
Maastricht, Netherlands) and taqmanprobe 5’-6FAM-
ACATACGATGCCYTCGGAGGATTCTG-BHQ-3’ (Tib
MolBiol, Berlin, Germany) were used. Template RNA
(5 μl) was added to a reaction mixture containing 0.25
μM of the forward and reverse primer, 0.25 μM probe,
2.75 mM MnCl2, 7.5 μl LightCycler mix and 0.2 μl
RNAsin (RNAsin, 40 U/μl, Promega Benelux b.v., Lei-
den, Netherlands) in a final volume of 20 μl. Thermocy-
cling conditions of the RT-PCR were: 20 s 98°C, 20 min
61°C, 30 s 95°C (1 s 95°C, 10 s 61°C, 15 s 72°C) × 45
cycles followed by 30 s 40°C and storage at 4°C. Ampli-
fication was monitored real-time by OD530/OD640
using LightCycler software version 4.05 (Roche Diagnos-
tics b.v., Almere, Netherlands).
For segment S7, 1 out of 30 cloned viruses contained S7
originating from BTV8/net06 (i.e BTV6/Net08/S78). This
finding was based on both positive and negative differen-
tiation; the presence of a PstI site in S7 of BTV8, and the
absence of a BglII site in case of S7 of BTV6 (Table 1, and
Figure 2, lane 8 and 9). Furthermore, the sequence of this
segment S7 was 100% identical to S7 of BTV8/net06. This
cloned virus was genetically serotyped as serotype 6,
whereas no detectable signal for serotype 8 was present
(Table 1). The unique combination of S2 of BTV6 and S7
originating from BTV8 clearly proves the presence of “syn-
thetic” reassortant virus BTV6/net08/S78 (Table 1).
For genome segment S10, 1 out of 24 tested clones con-
tained S10 originating from BTV8/net06 (i.e. BTV6/
Net08/S108) based on nucleotide differences on several
positions in the amplicon. Again, the presence and
absence of S2 of respectively serotype 6 and 8 was con-
firmed (Table 1). The “synthetic” reassortant BTV6/net08/
S108 also represents a unique combination of genome seg-
ments in one BTV not seen before.
In one occasion, we have also observed a mixture of
both segments S7 in candidate reassortant viruses
(Figure 2, lane 1). After six sequential and blind pas-
sages on BSR cells, a virus stock was obtained contain-
ing a majority S7 derived from BTV8 (Figure 2, lane 5).
After cloning by end-point dilution, only reassortant
BTV6 with S7 of BTV8, BTV6/net08/S78, was found
(Figure 2, lane 6 and 7). Enrichment of this in vitro res-
cued reassortant BTV after passaging suggests that this
reassortant benefits from S7 of BTV8. This is in agree-
ment with previous findings [10] in which also a positive
selection was suggested for the reassortant BTV6 with
Table 1 Characterization of reassortant viruses.
virus Genotyping
on S7
amplicona
Genotyping
on S10
ampliconb
BTV6
serotype
specific
PCRc
BTV8
serotype
specific
PCRd
BTV8/net06 8 8 - +
BTV6/net08 6 6 + -
BTV6/net08/
S78
8 6 + -
BTV6/net08/
S108
6 8 + -
a. S7 amplicons were digested with BglII and PstI and compared to that of
the parental strains, see also figure 2, lanes 8 and 9. b. S10 amplicons were
sequenced and compared to sequences of parental strains BTV8/net06 and
BTV6/net08. Genetic serotyping by serotype-specific real-time PCR-assays was
performed for serotypes 6 (c) and 8 (d). Presence or absence of a Cp-value
was interpreted as + and -, respectively.
Figure 2 Restriction enzyme analysis of amplicons derived
from S7 of different passages of a mixture of reassortant and
parental virus. Amplicons were digested with BglII and PstI.
Segment S7 of BTV8 (S78) digested with PstI (unique for S78) results
in fragments of 471 and 685 bps (see lane 8), whereas segment S7
of BTV6 (S76) digested with BglII (unique for S76) results in
fragments of 536 and 620 base pairs (bps) (see lane 9). Several blind
passages (p) of the initial mixture of reassortant BTV6/net08/S78 and
parental virus BTV6/net08 were analyzed by digestion with both
restriction enzymes; p1 (lane 1), p2 (lane 2), p4 (lane 3), p5 (lane 4),
and p6 (lane 5). Passage 6 was cloned by end point dilution and
two finally cloned reassortants BTV6/net08/S78 were passed twice
and analyzed (lanes 6 and 7). Analysis of amplicons derived from
segment S7 of BTV8/net06 and parental virus BTV6/net08 are
presented in lanes 8 and 9, respectively.
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segment S7 delivered by BTV8/net06. In order to study
whether reassortant viruses BTV6/net08/S78 and BTV6/
net08/S108 differ in growth characteristics, we deter-
mined growth curves on BSR cells. Therefore, confluent
monolayers of BSR cells in M24-well were infected at a
moi of 0.1 with BTV6/net08(e1/bhk3/bsr2), BTV8/net06
(e1/bhk3), BTV6/net08/S78(bsr2) and BTV6/net08/S108
(bsr2). After attachment to cells for 1.5 h at 37°C, super-
natant was removed and stored at -80°C (t = 0). One ml
of fresh DMEM with 5% FBS, 1% Penicillin/Streptomy-
cin/Fungizone was added to the monolayers and incuba-
tion was continued. At 21, 27, 45 and 79 hours post
infection (hpi), samples of the supernatants were har-
vested and stored at -80°C. Virus titers were determined
by end-point dilution. The observed differences in virus
titer at 0 hpi, which was approximately 10-fold higher
for BTV6/net08/S78 (Figure 3), reflect the amount of
non-attached virus. Starting from 21 hpi, virus titers in
supernatants were determined reflecting the production
of virus. In all samples of the growth curve, samples of
BTV6/net08/S78 contained a significant higher virus
titer, but the difference at the final sampling point (79
hpi) was minimal. Since no great differences in the
slopes of the different growth curves were detected, the
observed enrichment of this reassortant by passaging (6
times) of a mixture of BTV6/Net08 and BTV6/net08/
S78 could be the result of factors other than replication
and remains unclear.
Despite optimizing the uptake of an exogenous geno-
mic RNA-segment, the here described method to gener-
ate reassortants of bluetongue virus is not very efficient.
The percentage of rescued reassortant virus is approxi-
mately 3-5% for genome segments S7 and S10. However,
the method is relatively easy to perform, and mass
screening of reassortant candidates can be easily per-
formed depending on the targeted gene and available
tools, like discriminating Mabs and/or discriminating
PCR-assays. Particularly, this method is of interest for
research focusing on one genome segment, since a full
set of ten cDNAs encoding complete genome segments
is not required. Boyce et al [19] have developed a
method with a similar aim by mixing authentic core-
derived transcripts isolated from infected cells and plas-
mid-derived T7 transcript of which the efficiency was
15-80% to recover reassortant infectious BTV. This effi-
ciency is significantly higher than of the method
described here, but isolation and purification of intact
core-derived RNAs needs a lot of preparation.
The major drawback of the here described method is
the high percentage of parental virus not reassorting
with delivered in vitro synthesized RNA. On one hand,
the method could be significantly improved by reducing
this virus background with discriminating specific siR-
NAs. Very strong reduction of virus growth has been
published for African horse sickness virus, another ser-
ogroup of the genus Orbivirus [20]. On the other hand,
Figure 3 Growth curve of parental and reassortant BTVs. BSR monolayers were infected in duplicate by reassortant viruses BTV6/net08/S78,
BTV6/net08/S108 and parental virus BTV6/net08 and BTV8/net06 with 0.1 moi. At 0, 21, 27, 45 and 79 hours post infection, samples of 1 ml were
taken. The virus titer in collected samples were determined by end-point dilution.
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the amount of in vitro synthesized RNA in infected cells
could be further increased to improve the efficiency to
rescue reassortants. This could be achieved by in vivo
RNA synthesis by T7 RNA-polymerase expressing BSR
cells after transfection of plasmids containing cDNA of
a genome segment flanked by the T7 promoter and a
functional ribozyme sequence. Alternatively, repeated
transfection of in vitro synthesized RNA could increase
the presence of RNA in the BTV-infected cell. Using
reverse genetics, recently Matsuo et al. have shown that
repeated transfection of BTV transcripts strongly
improve the recovery of infectious BTV [21]. This sug-
gests a short half-life of transfected BTV-RNAs. Thus,
timing of RNA-delivery could be crucial for our method,
and can also be solved by the suggested repeated RNA
transfection or constitutive transcription of BTV-RNA
to increase the percentage of reassortants. Summarizing,
although this method is successful, we believe that this
method can be significantly improved to rescue reassor-
tant orbiviruses.
Likely, the first event, the uptake of the transfected
RNA by the replicating virus is a random process. This
makes this method also suitable for rescue of reassor-
tants with other genome segments. For instance to gen-
erate reassortant virus with a different serotype by
uptake of RNA of genome segment S2. For this special
case, neutralizing sera or neutralizing Mabs could be
used to further reduce the background of parental virus
and to screen for reassortant virus.
The developed method results in the uptake by repli-
cating BTV of RNA that was synthesized in vitro with
cDNA as template. This opens the opportunity to use
this method as genetic modification system for BTV by
uptake of mutated genome segments to study viral pro-
teins. However, we realize that rescue of mutant BTVs
with a lower fitness will be more difficult. Presumably,
significant improvement of the method is necessary for
this purpose by either lowering the virus background,
increase the chance on uptake of synthesized mutant
RNA, or both. However, the opposite was not seen,
reassortant BTV6/08/S78 was rescued with a similar effi-
ciency, although this reassortant multiplies to a higher
virus titer than the parental virus. Apparently, efficiency
of uptake of transfected synthetic RNA and cloning of
mutant virus is at least as important as growth charac-
teristics of desired mutant BTVs.
In conclusion, a targeted single-gene modification sys-
tem for BTV was successfully developed without use of
positive selection for rescued reassortants or desired
(mutant) viruses. This method is also applicable for
more detailed genetic modification of BTV to study
functions of viral proteins. In addition but not proven
here, the method could also be successful to incorporate
more than one genome segment, like genome segments
S2 and S6 encoding together the complete outer shell of
BTV. Finally, for other serogroups of the genus Orbi-
virus for which reverse genetics has not been developed
yet, such as Epizootic hemorrhagic disease virus, this
targeted single-gene modification system method will
also be applicable in order to generate mutant
orbiviruses.
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